MICRONOR by Johnson & Johnson is clinical pharmacology 1. First approved in 1973.
Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
MICRONOR is a progestin-only oral contraceptive (minipill) approved in 1973 for prevention of pregnancy. It works through multiple mechanisms including suppression of ovulation in ~50% of users, cervical mucus thickening, and endometrial alteration. The product represents a hormone-based small molecule approach to contraception with strict adherence requirements due to rapid drug elimination.
As a mature legacy product approaching loss of exclusivity, MICRONOR team size is likely stable or contracting, with focus on defending market share against competitive progestin-only and combined oral contraceptive alternatives.
CLINICAL PHARMACOLOGY 1. Mode of Action ORTHO MICRONOR progestin-only oral contraceptives prevent conception by suppressing ovulation in approximately half of users, thickening the cervical mucus to inhibit sperm penetration, lowering the midcycle LH and FSH peaks, slowing the movement of the ovum…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on MICRONOR offers exposure to mature product management, regulatory compliance, and market defense strategies in a stable but non-growth environment. This role suits professionals seeking deep expertise in contraceptive markets and legacy brand stewardship rather than high-velocity innovation careers.
Worked on MICRONOR at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.